Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncopeptides AB (CHIX:ONCOs) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Oncopeptides AB's Enterprise Value for the quarter that ended in Mar. 2026 was kr613.24 Mil.
Oncopeptides AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-202.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncopeptides AB EV-to-EBIT Related Terms
Oncopeptides AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Oncopeptides AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ONCOS vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Oncopeptides AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncopeptides AB EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncopeptides AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Oncopeptides AB's EV-to-EBIT falls into.
Oncopeptides AB's current Enterprise Value is kr538.49 Mil.
Oncopeptides AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-202.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncopeptides AB (CHIX:ONCOS) has a EV-to-EBIT of -2.66 as of Jul. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Oncopeptides AB and its competitors. According to the industry distribution chart, Oncopeptides AB ranks #999999 out of 381 companies in the Biotechnology industry.
Is Oncopeptides AB's EV-to-EBIT too high?
Oncopeptides AB's current EV-to-EBIT is -2.66. Based on the distribution chart, Oncopeptides AB ranks #999999 out of 381 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncopeptides AB has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncopeptides AB ranks #999999 out of 381 companies for EV-to-EBIT. This places Oncopeptides AB in the lower half of its industry. The industry median EV-to-EBIT is 12.81. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.81, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Oncopeptides AB and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncopeptides AB's current EV-to-EBIT is -2.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (CHIX:ONCOS) is currently considered Possible Value Trap. The stock's GF Value™ is kr5.80, compared to a current price of kr1.72 — trading 70.3% below its estimated fair value. The current EV-to-EBIT is -2.66. Oncopeptides AB's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Oncopeptides AB (CHIX:ONCOS), the current EV-to-EBIT is -2.66 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncopeptides AB (CHIX:ONCOS) Overvalued in 2026?
Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued.
The current stock price of kr1.72 is trading 70.3% below its estimated GF Value™ of kr5.80.
GuruFocus considers Oncopeptides AB to be Possible Value Trap.
Key valuation signals for CHIX:ONCOS:
EV-to-EBIT: -2.66
GF Value™: kr5.80 vs. price of kr1.72 (70.3% below fair value)
No single metric tells the full story. See the CHIX:ONCOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
46GF Score
Get the complete analysis for CHIX:ONCOS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONCOS has been successfully added to your 
